Literature DB >> 28920880

Edaravone for treatment of early-stage ALS.

Jesús S Mora1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28920880     DOI： 10.1016/S1474-4422(17)30289-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

Review 1.  Tau tubulin kinases in proteinopathy.

Authors:  Laura M Taylor; Pamela J McMillan; Brian C Kraemer; Nicole F Liachko
Journal:  FEBS J       Date:  2019-05-22       Impact factor: 5.542

2.  Early Signs of Neuroinflammation in the Postnatal Wobbler Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Maria Claudia Gonzalez Deniselle; Alejandro F De Nicola; Maria Meyer; Analia Lima
Journal:  Cell Mol Neurobiol       Date:  2022-10-11       Impact factor: 4.231

3.  Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.

Authors:  Qian Li; Yi Feng; Yingchao Xue; Xiping Zhan; Yi Fu; Gege Gui; Weiqiang Zhou; Jean-Philippe Richard; Arens Taga; Pan Li; Xiaobo Mao; Nicholas J Maragakis; Mingyao Ying
Journal:  Mol Neurodegener       Date:  2022-01-10       Impact factor: 14.195

4.  Effect of alpha-mangostin in the prevention of behavioural and neurochemical defects in methylmercury-induced neurotoxicity in experimental rats.

Authors:  Rakesh Sahu; Sidharth Mehan; Sumit Kumar; Aradhana Prajapati; Abdulrahman Alshammari; Metab Alharbi; Mohammed A Assiri; Acharan S Narula
Journal:  Toxicol Rep       Date:  2022-04-22

5.  Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.

Authors:  Amit U Joshi; Nay L Saw; Hannes Vogel; Anna D Cunnigham; Mehrdad Shamloo; Daria Mochly-Rosen
Journal:  EMBO Mol Med       Date:  2018-03       Impact factor: 12.137
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.